Collaborating and Competing in the Brave New Biotech World
Tony Jones, CEO, One Nucleus, Email: [email protected]
Is it new, another cycle or evolution of the biotech sector?
There have always been many pressures on the biotech industry innovation process. Limitations of existing technologies, sufficient understanding of biology, investment gaps, lack of available lab space to scale, lack of available talent to scale, changing regulations and more. Each of these hurdles has been addressed to a greater or lesser degree in numerous cycles throughout the decades of the…
By Natalie, Marketing Manager, One Nucleus
Are you considering joining 300+ life science professionals meeting at ON Helix 2026 on 9 July, and what are you hoping to get out of it?
Whether you are looking at sponsoring the conference to ensure your brand is visible on the conference communications, exhibiting to showcase your business to delegates, or simply attending to hear the keynote presentations and meet the ecosystem, here are some suggestions to help you make the most of your presence in the run-up to and during the conference.
Commit Early to Maximise Customer Touchpoints…
*Guest blog by Kat Arney, PhD. Founder and Chief Creative Officer, First Create The Media.
If you would like to submit a guest blog please email [email protected].
"The recent biotech funding environment has been horrible."
That was the blunt assessment from Altar Munis from Lifespan Vision Ventures, speaking at a recent Ones To Watch early-stage pitch event run by One Nucleus. I don’t think anyone in the room would have disagreed.
IPOs have been thin on the ground for several years, creating a liquidity crisis. And although there are signs that things are starting to pick up a…
*Guest blog by Professor Alan M. Palmer, Chief Executive Officer, Elixa MediScience.
If you would like to submit a guest blog please email [email protected].
The industry promised AI would transform medicine. Instead, it delivered a speed boost nobody needed and a clinical failure rate nobody fixed.
The pharmaceutical industry has spent the better part of a decade being told that artificial intelligence would transform drug discovery. The pitch was compelling: AI would slash development timelines, cut costs, and defeat diseases that had resisted human ingenuity for generations.…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Natalia Farr - [email protected].
If you would like to submit a guest blog please email [email protected].
Authors: Javier Ortega, Senior Medical Manager | Nicole Mielke, Patient Journey Services & Clinical Operations Director | Leen Mouazen, Business Development Associate at Pivotal
Clinical trials conducted in intensive care units (ICUs) represent one of the most complex and demanding areas of clinical research. Unlike more controlled therapeutic settings, ICUs…
by Tony Jones, CEO, One Nucleus
Email [email protected]
Michael Porter’s Cluster Theory, proposed over 40 years ago, was a watershed explanation of the value of like-minded stakeholders being in close proximity to drive innovation, growth, and in this context, translational research to create better patient outcomes.
The adage that success attracts success has also proven true when one looks at the enviable track record of success from leading international clusters such as Greater Boston, San Francisco, San Diego, Medicon Valley, the United Kingdom…
*Guest blog by LimestoneGrey. If you would like to submit a guest blog please email [email protected].
Protecting Your Business in a Higher-Scrutiny R&D Tax Landscape
R&D tax relief remains a valuable incentive for medtech and life sciences companies investing in genuine scientific and technological advancement. Whether a business is developing medical devices, diagnostic platforms, digital health technologies, therapeutics, clinical tools or advanced healthcare systems, R&D tax relief can provide vital support.
A Changing R&D Tax Relief Landscape
HMRC has significantly…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Eva Font, Regulatory and Start-up Director – Pivotal
How sponsors can leverage both the EU Clinical Trials Regulation and UK’s reformed framework to achieve cost efficiencies, faster timelines, and stronger regulatory positioning.
EXECUTIVE SUMMARYThe post-Brexit regulatory landscape has created a unique — and frequently underutilized — opportunity for…
*Guest blog by Romy Frow at Travel Counsellors. If you would like to submit a guest blog please email [email protected].
Business travel has always had a lot of moving parts: flights, hotels, ground transport, budgets and policies. Today, it also means navigating constantly changing geopolitics, airline schedule changes and sudden disruptions, such as the recent events and airspace restrictions in the Middle East.
If you are responsible for multiple travellers, complex itineraries or mission-critical journeys, the stakes are simply too high to leave travel to chance or rely on ad hoc…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Transforming Patient Care Through Innovation
Executive Summary
Drug-resistant epilepsy (DRE) affects approximately 15–16 million people worldwide1 — roughly 30% of all individuals with epilepsy. Despite optimal pharmacological therapy, patients experience profound impacts on safety, independence, cognitive function, and survival. The emergence of novel therapeutic agents…